| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Myovant Sciences (NYSE:MYOV) reported its Q2 earnings results on Wednesday, October 26, 2022 at 08:30 AM.
Here's what investors need to know about the announcement.
Myovant Sciences beat estimated earnings by 2.08%, reporting an EPS of $-0.47 versus an estimate of $-0.48.
Revenue was up $26.92 million from the same period last year.
Last quarter the company beat on EPS by $0.08 which was followed by a 8.01% increase in the share price the next day.
Here's a look at Myovant Sciences's past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.30 | -0.57 | -0.60 | -0.38 |
| EPS Actual | -0.22 | -0.63 | -0.68 | -0.23 |
| Revenue Estimate | 91.30M | 64.66M | 53.92M | 71.40M |
| Revenue Actual | 116.49M | 57.57M | 54.44M | 77.90M |
To track all earnings releases for Myovant Sciences visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: MYOV
